Mergers & Acquisitions - Biotechnology, Neurological

Filter

Current filters:

BiotechnologyNeurological

Popular Filters

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

03-06-2014

Israel generics giant Teva Pharmaceutical Industries has entered into a definitive agreement to acquire…

AmgenBiotechnologyLabrys BiologicsLBR-101Mergers & AcquisitionsNeurologicalTeva Pharmaceutical Industries

Lundbeck in deal to acquire Chelsea Therapeutics

Lundbeck in deal to acquire Chelsea Therapeutics

08-05-2014

Danish CNS specialist Lundbeck revealed today that it has entered into a definitive agreement to acquire…

BiotechnologyChelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNorthera

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

30-04-2014

US pharma major Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused…

BiotechnologyBristol-Myers SquibbiPierianIPN007Mergers & AcquisitionsNeurological

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Sangamo BioSciences to buy Ceregene

28-08-2013

In its first takeover bid since 2001, US drugmaker Sangamo BioSciences (Nasdaq: SGMO) has signed a definitive…

BiotechnologyCERE-110CeregeneMergers & AcquisitionsNeurologicalOphthalmicsSangamo BioSciences

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate

04-06-2013

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Canada's Pharmascience sets up JV with Korea Kolmar; buys Rivex

03-01-2013

Privately-held Canadian drugmaker Pharmascience and Korea Kolmar Holdings, based in Seoul, South Korea,…

Asia-PacificBiotechnologyGenericsHelix BioPharmaKorea KolmarMergers & AcquisitionsNeurologicalNorth AmericaPharmaceuticalPharmascienceRivex Pharma

Briefs: Takeda and Lundbeck file vortioxetine NDA; Merck Serono spin-out

03-10-2012

Japan's biggest drugmaker Takeda Pharmaceutical (TYO: 4502) and partner Danish CNS specialist Lundbeck…

AsceneurionBiotechnologyLundbeckMerck KGaAMerck SeronoMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvortioxetine

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Cortex and Pier Pharma in all-share merger

15-08-2012

USA-based neuroscience company Cortex Pharmaceuticals (OTCBB: CORX) and privately held biotech firm Pier…

BiotechnologyCortex PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceuticalPier Pharmaceuticals

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

Grifols acquires 51% stake in Araclon Biotech

19-03-2012

Spanish plasma products specialist Grifols (MCE: GRF) has acquired 51% of the equity of Zaragoza, Spain-based…

Araclon BiotechBiotechnologyGrifolsMergers & AcquisitionsNeurologicalPharmaceuticalVaccines

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research

16-10-2011

Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

27-09-2011

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top